
Sanofi will pay Regeneron $582m in deal restructuring
pharmafile | January 7, 2019 | News story | Sales and Marketing |Â Â Deals, Regeneron, Sanofi, biotech, pharmaÂ
French pharmaceutical giant Sanofi will pay US biotech Regeneron $582 million, as part of a restructuring of an earlier deal between the two firms.
It is hoped that the new arrangement will offer Sanofi increased flexibility in advancing its early-stage immuno-oncology pipeline independently.
Meanwhile Regeneron will retain all rights to its other immuno-oncology discovery and development programmes.
Sanofi will pay Regeneron an initial sum of $462 million, which will cover Sanofi’s share of the costs for the immuno-oncology discovery programme for the last quarter of 2018, as agreed under the original terms of the deal set in 2015.
Sanofi will also pay an additional $120 million, which will cover other development costs for two selected clinical-stage bispecific antibodies, plus the termination fee for the other programs under the original immuno-oncology agreement. The original deal was scheduled to end in approximately mid-2020.
The agreement will secure Sanofi’s right to opt-in to the BCMAxCD3 and MUC16xCD3 bispecific programs when proof of concept is achieved or when the allocated funding is expended.
Louis Goss
Related Content

Arkin Capital closes $100m fund for pre-clinical and early clinical-stage biotech
Arkin Capital has announced the closing of Arkin Bio Ventures III, a $100m fund designed …

Cellbyte raises $2.75m to fund pharma drug launch platform
Cellbyte has announced that it has raised $2.75m in seed funding for the streamlining of …

Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …






